PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21095460-1 2010 Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. Levodopa 157-163 catechol-O-methyltransferase Mus musculus 0-28 21095460-1 2010 Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. Levodopa 157-163 catechol-O-methyltransferase Mus musculus 30-34 21095460-3 2010 Bioavailability and efficacy of L-dopa treatment can be enhanced greatly by the use of COMT inhibitors. Levodopa 32-38 catechol-O-methyltransferase Mus musculus 87-91 19930170-0 2009 Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. Levodopa 61-67 catechol-O-methyltransferase Mus musculus 29-57 19930170-12 2009 CONCLUSIONS AND IMPLICATIONS: In S-COMT-deficient mice, MB-COMT in the liver and the duodenum is able to O-methylate about one-half of exogenous L-DOPA. Levodopa 145-151 catechol-O-methyltransferase Mus musculus 35-39 19930170-12 2009 CONCLUSIONS AND IMPLICATIONS: In S-COMT-deficient mice, MB-COMT in the liver and the duodenum is able to O-methylate about one-half of exogenous L-DOPA. Levodopa 145-151 catechol-O-methyltransferase Mus musculus 59-63 14574438-5 2004 Further, when COMT knockout mice were challenged with l-dopa or a dopamine transporter (DAT) inhibitor, an accumulation of dopamine occurred and the neurochemical and locomotor effects of l-dopa and GBR 12909 were modified accordingly. Levodopa 188-194 catechol-O-methyltransferase Mus musculus 14-18 19426692-1 2009 Catechol-O-methyl transferase (COMT) methylates catechols, such as L-dopa and dopamine, and COMT deficient mice show dramatic shifts in the metabolite levels of catechols. Levodopa 67-73 catechol-O-methyltransferase Mus musculus 0-29 19426692-1 2009 Catechol-O-methyl transferase (COMT) methylates catechols, such as L-dopa and dopamine, and COMT deficient mice show dramatic shifts in the metabolite levels of catechols. Levodopa 67-73 catechol-O-methyltransferase Mus musculus 31-35 14574438-5 2004 Further, when COMT knockout mice were challenged with l-dopa or a dopamine transporter (DAT) inhibitor, an accumulation of dopamine occurred and the neurochemical and locomotor effects of l-dopa and GBR 12909 were modified accordingly. Levodopa 54-60 catechol-O-methyltransferase Mus musculus 14-18 14654758-10 2003 At baseline, 24-h urinary excretion of levodopa (L-DOPA), dopamine and noradrenaline was increased by 145, 85 and 74%, respectively, in COMT (-/-) mice compared with wild-type controls. Levodopa 39-47 catechol-O-methyltransferase Mus musculus 136-140 14654758-10 2003 At baseline, 24-h urinary excretion of levodopa (L-DOPA), dopamine and noradrenaline was increased by 145, 85 and 74%, respectively, in COMT (-/-) mice compared with wild-type controls. Levodopa 49-55 catechol-O-methyltransferase Mus musculus 136-140 14654758-12 2003 The absolute amounts of urinary L-DOPA and dopamine remained 60 and 20% greater in COMT (-/-) mice. Levodopa 32-38 catechol-O-methyltransferase Mus musculus 83-87 11849292-7 2002 In contrast, when COMT-deficient mice are challenged with l-dihydroxyphenylalanine, they show an extensive accumulation of 3,4-dihydroxyphenylacetic acid and dihydroxyphenylglycol and even dopamine, revealing an important role for COMT under such situations. Levodopa 58-82 catechol-O-methyltransferase Mus musculus 18-22 12597016-7 2002 L-dopa plus carbidopa or OR-486 (a potent centrally acting COMT inhibitor) completely reversed adenosine-induced catatonia. Levodopa 0-6 catechol-O-methyltransferase Mus musculus 59-63 11849292-7 2002 In contrast, when COMT-deficient mice are challenged with l-dihydroxyphenylalanine, they show an extensive accumulation of 3,4-dihydroxyphenylacetic acid and dihydroxyphenylglycol and even dopamine, revealing an important role for COMT under such situations. Levodopa 58-82 catechol-O-methyltransferase Mus musculus 231-235 11980384-19 2002 It is concluded that COMT and MAO-B enzymes play an important role in the metabolism of dopamine and administration of a COMT or MAO-B inhibitor may prove to be a better adjunct to L-DOPA therapy than a dopamine receptor agonist in Parkinson"s disease. Levodopa 181-187 catechol-O-methyltransferase Mus musculus 21-25 11980384-19 2002 It is concluded that COMT and MAO-B enzymes play an important role in the metabolism of dopamine and administration of a COMT or MAO-B inhibitor may prove to be a better adjunct to L-DOPA therapy than a dopamine receptor agonist in Parkinson"s disease. Levodopa 181-187 catechol-O-methyltransferase Mus musculus 121-125 8785021-0 1995 Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. Levodopa 58-64 catechol-O-methyltransferase Mus musculus 33-37 33269743-1 2021 Entacapone, a catechol-O-methyltransferase inhibitor, can strengthen the therapeutic effects of levodopa on the treatment of Parkinson"s disease. Levodopa 96-104 catechol-O-methyltransferase Mus musculus 14-42 1005491-9 1976 This discrepancy may be explained by high doses of L-DOPA causing inhibiton of catechol-O-methyl transferase (COMT), which is suggested by the observation that the forebrain homovanillic acid (HVA): 3,4-dihydroxyphenylacetic acid (DOPAC) ratio was significantly lower after the high dose of L-DOPA than in untreated mice. Levodopa 51-57 catechol-O-methyltransferase Mus musculus 79-108 1005491-9 1976 This discrepancy may be explained by high doses of L-DOPA causing inhibiton of catechol-O-methyl transferase (COMT), which is suggested by the observation that the forebrain homovanillic acid (HVA): 3,4-dihydroxyphenylacetic acid (DOPAC) ratio was significantly lower after the high dose of L-DOPA than in untreated mice. Levodopa 51-57 catechol-O-methyltransferase Mus musculus 110-114 1005491-9 1976 This discrepancy may be explained by high doses of L-DOPA causing inhibiton of catechol-O-methyl transferase (COMT), which is suggested by the observation that the forebrain homovanillic acid (HVA): 3,4-dihydroxyphenylacetic acid (DOPAC) ratio was significantly lower after the high dose of L-DOPA than in untreated mice. Levodopa 291-297 catechol-O-methyltransferase Mus musculus 79-108 1005491-9 1976 This discrepancy may be explained by high doses of L-DOPA causing inhibiton of catechol-O-methyl transferase (COMT), which is suggested by the observation that the forebrain homovanillic acid (HVA): 3,4-dihydroxyphenylacetic acid (DOPAC) ratio was significantly lower after the high dose of L-DOPA than in untreated mice. Levodopa 291-297 catechol-O-methyltransferase Mus musculus 110-114 32441567-4 2022 In addition, we analyzed the association with clinical factors and evaluated whether clinical factors affected the COMT inhibitory activity of bLF in vitro.Results: Although not statistically significant, the peak plasma concentration (Cmax) of levodopa increased by 18.5%. Levodopa 245-253 catechol-O-methyltransferase Mus musculus 115-119 28375049-2 2018 Catechol-O-methyltransferase (COMT) is involved in the O-methylation of l-DOPA, dopamine, and other catechols. Levodopa 72-78 catechol-O-methyltransferase Mus musculus 0-28 28375049-2 2018 Catechol-O-methyltransferase (COMT) is involved in the O-methylation of l-DOPA, dopamine, and other catechols. Levodopa 72-78 catechol-O-methyltransferase Mus musculus 30-34 28315782-1 2017 Catechol-O-methyltransferase (COMT) degrades dopamine and its precursor l-DOPA and plays a critical role in regulating synaptic dopamine actions. Levodopa 72-78 catechol-O-methyltransferase Mus musculus 0-28 28315782-1 2017 Catechol-O-methyltransferase (COMT) degrades dopamine and its precursor l-DOPA and plays a critical role in regulating synaptic dopamine actions. Levodopa 72-78 catechol-O-methyltransferase Mus musculus 30-34 28195063-2 2016 COMT is involved in the O-methylation of L-DOPA, dopamine and other catechols. Levodopa 41-47 catechol-O-methyltransferase Mus musculus 0-4 7957769-7 1994 In conclusion, the inhibitory effect of tolcapone on the O-methylation of levodopa to 3-OMD by COMT is largely due to improved levodopa and dopamine availability in the brain, and to the reduced formation of 3-OMD. Levodopa 74-82 catechol-O-methyltransferase Mus musculus 95-99 7957769-7 1994 In conclusion, the inhibitory effect of tolcapone on the O-methylation of levodopa to 3-OMD by COMT is largely due to improved levodopa and dopamine availability in the brain, and to the reduced formation of 3-OMD. Levodopa 127-135 catechol-O-methyltransferase Mus musculus 95-99